The pharmacokinetic and pharmacodynamic properties of vancomycin.

By M. Rybak. Clinical Infectious Diseases, 2006

769 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. (2019, methodology): “Because the AUC/MIC has been found to correlate with efficacy in experiments conducted with in vitro or animal models, this evidence has led some clinicians to question the relevance of monitoring peak serum vancomycin concentrations.(6) Consequently, some clinicians have decreased the extent of pha”
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. (2006, background): “Duration of vancomycin therapy, mean (range), d 17 (13-54) 11 (6-15) .”
Pharmacokinetic issues for antibiotics in the critically ill patient (2009, background): “Other studies have proposed that AUC:MIC is the pharmacokinetic and pharmacodynamic parameter correlated with efficacy (10, 99).”